Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17602119 | 0.84 | KDM4C (0.69) | KDM4C | |
| SCHEMBL29542310 | 0.84 | KDM4C (0.69) | KDM4C | |
| SCHEMBL19268159 | 0.78 | KDM4C (0.43) | KDM4C | |
| SCHEMBL19268161 | 0.76 | LATS1 (0.42) | KDM4C | |
| SCHEMBL19268158 | 0.76 | EGFR (0.43) | KDM4C | |
| SCHEMBL22163336 | 0.75 | KDM4C (0.50) | KDM4C | |
| SCHEMBL19268162 | 0.75 | MTNR1A (0.44) | KDM4C | |
| SCHEMBL19268156 | 0.74 | EGFR (0.38) | KDM4C | |
| SCHEMBL29874566 | 0.74 | MC4R (0.50) | KDM4CCHKA | |
| SCHEMBL17602275 | 0.74 | MC4R (0.50) | KDM4CCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815234-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | KDM4C 9/4885AOC3 2639/4885CHKA 879/4885 |
| US-10815234-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | KDM4C 9/4885AOC3 2639/4885CHKA 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.